Alaunos Therapeutics

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

Alaunos Therapeutics’ mission is to deliver life-saving treatments to patients and caregivers impacted by serious, life-threatening diseases.

Alaunos Therapeutics’ vision is to become a global leader in developing and delivering cutting-edge treatments and therapies that will revolutionize the treatment and management of serious, life-threatening diseases.

Alaunos Therapeutics has been recognized for its innovative therapies, such as the 2017 Global Challenge Award from the Bill and Melinda Gates Foundation and a Medal of Excellence from the American Academy of Sciences.